US SEC Trading Suspension Halt Orders — July 02, 2026

02-07-2026

RenovoRx, Inc. (RNXT) received a second 180-day extension from Nasdaq, until December 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company failed to meet the original compliance deadline of June 30, 2026, and must now maintain a closing bid price of at least $1.00 for 10 consecutive business days during the Second Compliance Period.

• · Original deficiency notice received December 31, 2025, with first compliance deadline of June 30, 2026.
• · If not compliant by December 28, 2026, Nasdaq will issue a delisting notice; the company may appeal to a Hearings Panel.
• · Company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.

02-07-2026

HeartBeam, Inc. received a Nasdaq deficiency notice on June 30, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has a 180-day compliance period until December 28, 2026, to regain compliance, and may qualify for a second 180-day period if it meets other listing standards. There is no immediate impact on listing, but failure to regain compliance could lead to delisting.

• · The company's common stock trades under the symbol BEAT on the Nasdaq Capital Market.
• · The company's warrants trade under the symbol BEATW on the Nasdaq Capital Market.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
• · If the company fails to regain compliance by December 28, 2026, it may be eligible for a second 180-day compliance period if it meets the market value of publicly held shares requirement and all other initial listing standards except the minimum bid price.

02-07-2026

Boxlight Corp received a Nasdaq delisting notice on July 1, 2026 for failing to meet the $2.5 million stockholders' equity requirement. The company plans to request a hearing to appeal the suspension and is exploring financing alternatives, including a potential stock issuance approved by shareholders on June 2, 2026. However, there is no assurance the Panel will grant continued listing or that Boxlight can regain compliance within any extension period.

• · The delisting notice was received on July 1, 2026, and the 8-K was filed on July 2, 2026.
• · Shareholders approved potential issuance of 20% or more of outstanding Class A Common Stock at the annual meeting on June 2, 2026.
• · The company is exploring financing alternatives but has not yet entered into a definitive agreement.
• · There is no assurance the Panel will grant continued listing or that Boxlight can demonstrate compliance within any extension period.

02-07-2026

On July 1, 2026, AI Financial Corporation (AIFC) received a Nasdaq notification that its common stock has failed to maintain the minimum $1.00 bid price for 30 consecutive business days, making it non-compliant with continued listing rules. The company has a 180-day cure period (until December 28, 2026) to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days. AIFC intends to explore options including a potential reverse stock split to remedy the deficiency, but faces delisting risk if compliance is not achieved within the cure period.

• · The deficiency period ended on June 30, 2026, which was the 30th consecutive business day of non-compliance.
• · If compliance is not regained by December 28, 2026, Nasdaq may grant an additional 180 days, subject to meeting other listing standards (excluding the bid price rule) and a written notice of intent to cure.
• · If the company fails both cure periods, Nasdaq will notify AIFC of a delisting determination, after which the company may appeal to a Hearings Panel.

02-07-2026

FingerMotion, Inc. (FNGR) received a Nasdaq deficiency letter on June 30, 2026, for trading below the $1.00 minimum bid price for 30 consecutive business days. The company has until December 28, 2026, to regain compliance, with a possible second 180-day period if certain conditions are met. The company may consider a reverse stock split but cannot assure compliance.

• · Nasdaq Deficiency Letter received on June 30, 2026.
• · Compliance deadline: December 28, 2026.
• · To regain compliance, stock must close at $1.00 or more for at least 10 consecutive business days.
• · If a reverse stock split is used, it must be completed 10 business days before the Compliance Date.
• · A second 180-day period may be available if the company meets other listing standards and notifies Nasdaq of its intent to cure.
• · Failure may lead to delisting, with a possible appeal to a Hearings Panel, but success is not assured.

02-07-2026

Callan JMB Inc. (CJMB) received a Nasdaq notice on June 29, 2026, for failing to maintain the minimum $1.00 bid price over 30 consecutive business days. The company has a 180-day compliance period until December 28, 2026, to regain compliance, with a potential additional 180-day period if certain conditions are met. While the stock continues trading for now, the company faces a material risk of delisting if it cannot cure the deficiency, and management is considering options including a reverse stock split.

• · The company is an emerging growth company as defined under SEC rules.
• · The company has not elected to use the extended transition period for complying with new financial accounting standards.
• · If the company does not regain compliance by December 28, 2026, it may be eligible for an additional 180-day compliance period if it meets all other initial listing standards except the bid price requirement and notifies Nasdaq in writing of its intent to cure.
• · If delisting proceeds, the company may appeal Nasdaq's determination to a Nasdaq Hearings Panel.
• · The company's common stock continues to trade on The Nasdaq Capital Market under the symbol 'CJMB' with no immediate effect on listing.

02-07-2026

MV Oil Trust announced its final quarterly distribution of $6,829,206 ($0.593844 per unit) for the period ended June 30, 2026, and simultaneously disclosed the termination of its net profits interest due to minimum production thresholds being met, dissolution of the Trust, and voluntary delisting from the NYSE. The Trust will wind up with no further distributions, and expects unit prices to decline to zero. Positive aspects include the release of capital expenditure reserves and trustee expense reserves boosting the final payout, but the trust's complete termination and zero future value for units are negative for ongoing investors.

• · The Trust dissolved as of June 30, 2026 because the minimum production threshold of 14.4 MMBoe (equivalent to 11.5 MMBoe for the Trust's 80% interest) was met.
• · No further distributions will be paid after the final payment on July 24, 2026.
• · The market price of Trust units is expected to decline to zero by the time of final distribution.
• · Delisting of Trust Units from NYSE will occur before market open on July 27, 2026.
• · Trust intends to file Form 15 to terminate registration and suspend reporting obligations; no Form 10-Q for Q2 2026 will be filed—only a report on the Trust website within 75 days.
• · The Trustee built a $1,265,000 cash reserve from Q1 2022 to Q2 2023; the remaining balance after prior expense payments is included in the final distribution.
• · Volumes for the final period were 140,993 BOE; gross proceeds $12,911,770; costs $6,244,609.